NASDAQ:CFRX - ContraFect Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.54 -0.05 (-8.49 %) (As of 04/18/2019 04:00 PM ET)Previous Close$0.59Today's Range$0.53 - $0.5852-Week Range$0.35 - $2.93Volume742,845 shsAverage Volume1.39 million shsMarket Capitalization$42.81 millionP/E RatioN/ADividend YieldN/ABeta-0.52 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York. Receive CFRX News and Ratings via Email Sign-up to receive the latest news and ratings for CFRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CFRX Previous Symbol CUSIPN/A CIK1478069 Webwww.contrafect.com Phone914-207-2300Debt Debt-to-Equity RatioN/A Current Ratio5.42 Quick Ratio5.42Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book7.70Profitability EPS (Most Recent Fiscal Year)($0.37) Net Income$-37,680,000.00 Net MarginsN/A Return on Equity-1,086.30% Return on Assets-72.03%Miscellaneous Employees20 Outstanding Shares79,410,000Market Cap$42.81 million Next Earnings Date5/9/2019 (Estimated) OptionableNot Optionable ContraFect (NASDAQ:CFRX) Frequently Asked Questions What is ContraFect's stock symbol? ContraFect trades on the NASDAQ under the ticker symbol "CFRX." How were ContraFect's earnings last quarter? ContraFect Corp (NASDAQ:CFRX) issued its earnings results on Thursday, March, 14th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.17. View ContraFect's Earnings History. When is ContraFect's next earnings date? ContraFect is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for ContraFect. What price target have analysts set for CFRX? 3 equities research analysts have issued 1 year price objectives for ContraFect's stock. Their forecasts range from $2.80 to $2.80. On average, they expect ContraFect's stock price to reach $2.80 in the next year. This suggests a possible upside of 419.4% from the stock's current price. View Analyst Price Targets for ContraFect. What is the consensus analysts' recommendation for ContraFect? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ContraFect. Has ContraFect been receiving favorable news coverage? Media coverage about CFRX stock has trended positive this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ContraFect earned a daily sentiment score of 2.4 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. Who are some of ContraFect's key competitors? Some companies that are related to ContraFect include Adamas Pharmaceuticals (ADMS), Zynerba Pharmaceuticals (ZYNE), BELLUS Health (BLUSF), REDHILL BIOPHAR/S (RDHL), Menlo Therapeutics (MNLO), AgeX Therapeutics (AGE), Tyme Technologies (TYME), Newron Pharmaceuticals (NWPHF), Axovant Sciences (AXGT), Verastem (VSTM), Galmed Pharmaceuticals (GLMD), Syndax Pharmaceuticals (SNDX), Aquestive Therapeutics (AQST), LifeVantage (LFVN) and Humanigen (HGEN). What other stocks do shareholders of ContraFect own? Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include Catalyst Pharmaceuticals (CPRX), Edge Therapeutics (EDGE), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Viking Therapeutics (VKTX), Antares Pharma (ATRS), Cara Therapeutics (CARA), Inovio Pharmaceuticals (INO) and Celldex Therapeutics (CLDX). Who are ContraFect's key executives? ContraFect's management team includes the folowing people: Dr. Steven C. Gilman, Exec. Chairman, CEO & Pres (Age 66)Mr. Michael Messinger CPA, CPA, CFO & Chief Accounting Officer (Age 44)Ms. Nancy Dong, VP of Fin. & Admin. (Age 54)Ms. Natalie Bogdanos J.D., Gen. Counsel, Corp. Sec. & Data Protection Officer (Age 50)Dr. Cara Cassino, Chief Medical Officer and Exec. VP of R&D (Age 57) Who are ContraFect's major shareholders? ContraFect's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Hartwell J M Limited Partnership (0.13%). Company insiders that own ContraFect stock include Cara M Cassino, Fosun Pharmaceutical Shanghai, Joshua B Muntner, Sol J Barer and Steven C Gilman. View Institutional Ownership Trends for ContraFect. Which institutional investors are buying ContraFect stock? CFRX stock was acquired by a variety of institutional investors in the last quarter, including Hartwell J M Limited Partnership. Company insiders that have bought ContraFect stock in the last two years include Cara M Cassino, Joshua B Muntner, Sol J Barer and Steven C Gilman. View Insider Buying and Selling for ContraFect. How do I buy shares of ContraFect? Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ContraFect's stock price today? One share of CFRX stock can currently be purchased for approximately $0.5391. How big of a company is ContraFect? ContraFect has a market capitalization of $42.81 million. The biotechnology company earns $-37,680,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. ContraFect employs 20 workers across the globe. What is ContraFect's official website? The official website for ContraFect is http://www.contrafect.com. How can I contact ContraFect? ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected] MarketBeat Community Rating for ContraFect (NASDAQ CFRX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 160 (Vote Outperform)Underperform Votes: 136 (Vote Underperform)Total Votes: 296MarketBeat's community ratings are surveys of what our community members think about ContraFect and other stocks. Vote "Outperform" if you believe CFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/18/2019 by MarketBeat.com StaffFeatured Article: What impact do institutional investors have on markets?